Epitalon (AEDG): Telomerase and Chromatin Studies

Epitalon is four amino acids long: Ala-Glu-Asp-Gly, written AEDG in the Russian papers where nearly all the work on it happened. Roughly 390 daltons, which is about as small as a peptide gets, and that smallness is half the reason it behaves nothing like a receptor-targeted compound. The published record here is thin and comes from very few groups, so secondhand summaries of it drift badly. We went back to the papers. Below is what they report, plus the analytical end of handling the material.

Four residues, and what follows from that

Two acidic side chains, glutamate and aspartate, and not one aromatic residue. Consequences follow directly: it dissolves readily in water, it barely absorbs UV above 220 nm, and it has none of the hydrophobic surface that usually buries a peptide in a receptor pocket. Small, heavily charged peptides also tend to disappear from circulation fast. None of that makes a good candidate for ordinary receptor pharmacology.

Which raises the obvious question: by what mechanism would a tetrapeptide do anything at all? The proposal from Khavinson’s group is that it acts in the nucleus, interacting directly with DNA or with histones rather than with a cell surface receptor [7]. That is an unusual claim, and it is the part of this literature that deserves the most scrutiny.

The telomerase experiments

Some background first. Greider and Blackburn found telomerase in 1985, as an activity in Tetrahymena extracts that stuck tandem TTGGGG repeats onto synthetic telomere primers [1]. Hayflick and Moorhead had already shown that normal human diploid cells quit dividing after a finite run of passages [8]. Bodnar’s group closed the circle in 1998, putting the catalytic subunit into telomerase-negative human cells and watching the telomeres lengthen while the cells kept going [9]. Read the Epitalon papers against that, not in isolation.

Against that background, Khavinson, Bondarev and Butyugov reported in 2003 that adding Epitalon to telomerase-negative human fetal fibroblast cultures induced expression of the catalytic subunit, telomerase activity and telomere elongation [2]. The 2004 follow-up used primary pulmonary fibroblasts from a 24-week fetus that had lost proliferative potential at passage 34. Peptide-treated cells with elongated telomeres completed 10 further passages, reaching 44, and were still dividing when reported [3].

Our honest read: these are interesting in vitro observations from a single group, published in a journal with limited reach, and as far as we can find they have not been independently reproduced in the Western literature. The 1998 Bodnar work shows what a well controlled telomerase result looks like [9]. Compare them yourself before you take the tetrapeptide result at face value.

What the animal study measured

Anisimov and colleagues ran the longest study, in 54 female outbred Swiss-derived SHR mice per group, given either saline or 1.0 microgram of the tetrapeptide on 5 consecutive days each month from 3 months of age until natural death [4]. The results are more mixed than the usual summaries suggest:

Note the first two rows. Mean life span did not move. Secondary sources that cite this paper as a life extension result are quoting the tail of the survival curve and leaving out the average, which is exactly the kind of selective reading that makes this compound’s reputation hard to assess.

Chromatin and gene expression work

A second line of work looks at chromatin state. Khavinson and colleagues studied cultured lymphocytes from people aged 76 to 80 and reported activation of ribosomal genes, decondensation of pericentromeric structural heterochromatin, and release of genes repressed by condensation of euchromatic regions [5]. Lezhava and co-authors reported comparable effects for Epitalon alongside two other short peptides, Livagen and Vilon, in lymphocytes from donors aged 75 to 88 [6].

The 2020 paper is the most mechanistically specific of the set. Working in human gingival mesenchymal stem cells, Khavinson’s group measured increases of 1.6 to 1.8 fold in mRNA for Nestin, GAP43, beta tubulin III and doublecortin, with corresponding protein increases, and used molecular modelling to propose binding to histones H1/3 and H1/6 at the His-Pro-Ser-Tyr-Met-Ala-His-Pro-Ala-Arg-Lys and Tyr-Arg-Lys-Thr-Gln sites that contact DNA [7]. Modelling is a hypothesis, not a measurement, and the authors present it that way.

So the mechanistic picture across these papers is a peptide proposed to act epigenetically rather than through a receptor. It is coherent as a hypothesis. It is also thinly supported, and we would not describe it as established.

Reading this literature without getting burned

Things we’d keep in view while reading any of it:

• Nearly all the primary work traces to one institute in St Petersburg, much of it in journals with small circulation and patchy indexing.
• Replication from outside that group is sparse. Not proof of anything either way, but it’s the most useful single fact about this compound.
• Epitalon, Epithalon and AEDG peptide all refer to the same tetrapeptide in these papers, which makes literature searching messier than it should be.
• Epithalamin, a pineal extract used in some of the older Russian work, is a different preparation entirely and its results should not be transferred across.

That last point catches people constantly. If a claim traces back to an extract rather than to the synthetic tetrapeptide, it is a different experiment.

Characterisation and handling

Because the molecule has no tryptophan, tyrosine or phenylalanine, UV detection at 280 nm is useless for it and chromatography is run at low wavelength instead. It is also very polar, so it elutes early on reversed phase columns and needs ion pairing to retain usefully. Both facts make a bare “HPLC purity” figure less informative here than it would be for a larger peptide, and mass spectrometric confirmation of the 390 dalton mass matters more.

What a complete analytical record covers:

• Reversed phase HPLC purity, with the detection wavelength stated.
• Mass spectrometry confirming molecular weight, and MS/MS confirming residue order.
• Water content and counterion content, since those decide how much of the vial mass is peptide.
• Appearance and solubility, which is where visibly poor material announces itself first.

We publish the reports for our material on the COA page, and the testing workflow behind them is described in our article on third party tested material. For background on how short synthetic sequences like this one are assembled, see our overview of peptides and polypeptides.

Storage is the usual lyophilised peptide story: cold, dry, dark. Those glutamate and aspartate side chains make pH-driven chemistry the main degradation route once it’s wet, so expect solutions to have a much shorter life than the powder.

FAQ

Are Epitalon and Epithalon the same compound?

Yes. Both spellings, plus AEDG peptide, refer to Ala-Glu-Asp-Gly in the published literature [7].

Has the telomerase finding been replicated?

Not that we can find outside the original group. The 2003 and 2004 reports both come from the St Petersburg Institute of Bioregulation and Gerontology [2][3].

Did the mouse study show longer average survival?

No. Mean life span was unchanged; the differences were in the last 10 percent of survivors and in maximum life span [4].

References

1. Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell. 1985. PMID 3907856
2. Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003. PMID 12937682
3. Khavinson VKh, Bondarev IE, Butyugov AA, Smirnova TD. Peptide promotes overcoming of the division limit in human somatic cell. Bull Exp Biol Med. 2004. PMID 15455129
4. Anisimov VN, Khavinson VKh, Popovich IG, et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003. PMID 14501183
5. Khavinson VKh, Lezhava TA, Monaselidze JR, et al. Peptide Epitalon activates chromatin at the old age. Neuro Endocrinol Lett. 2003. PMID 14647006
6. Lezhava T, Monaselidze J, Kadotani T, Dvalishvili N, Buadze T. Anti-aging peptide bioregulators induce reactivation of chromatin. Georgian Med News. 2006. PMID 16705247
7. Khavinson V, Diomede F, Mironova E, et al. AEDG peptide (Epitalon) stimulates gene expression and protein synthesis during neurogenesis: possible epigenetic mechanism. Molecules. 2020. PMID 32019204
8. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res. 1961. PMID 13905658
9. Bodnar AG, Ouellette M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells. Science. 1998. PMID 9454332